Severe mitral regurgitation (MR) in patients after cardiac transplant has not been well studied. Traditionally, patients have undergone corrective surgery. We report a 64-year-old man who presented with new heart failure symptoms 6 months after cardiac transplantation. He was found to have severe MR and underwent successful implantation of a MitraClip ® with reduction of his MR to mild as well as improvement in his symptoms. Six months later he was still doing well, and a repeat echocardiogram showed good results. We found two previously reported cases using the MitraClip to treat severe MR in adult cardiac transplant patients. The MitraClip is a viable treatment option for MR in cardiac transplant patients despite their distorted anatomy.
I
n nontransplant patients at prohibitive surgical risk, the MitraClip ® (Abbot Vascular, Santa Clara, CA) provides a therapeutic treatment option for mitral regurgitation (MR). Th e MitraClip is a Food and Drug Administrationapproved percutaneous mitral valve repair system for severe degenerative MR. Current trials are evaluating its role in functional regurgitation. Th e system utilizes a cobalt-chromium clip covered with a polypropylene fabric to grasp the mitral leafl ets, thus reducing regurgitation by increasing leafl et coaptation. Insertion of the MitraClip is a challenging procedure and must be performed by a welltrained team under fluoroscopic and echocardiographic guidance.
Traditionally, severe mitral valve disease after transplantation has been addressed by a surgical approach (1) (2) (3) . Unfortunately, many patients may be at high surgical risk for complications due to comorbidities, functional status, and need for repeat sternotomy. It has not been well studied how best to treat these high-risk patients and whether the MitraClip is a feasible and safe option in this population.
CASE PRESENTATION
A 64-year-old man with idiopathic dilated cardiomyopathy underwent cardiac transplantation for end-stage heart Use of a MitraClip for severe mitral regurgitation in a cardiac transplant patient failure. He had a prolonged postoperative course complicated by primary graft dysfunction, respiratory failure requiring tracheostomy, renal failure, and malnutrition. After an extended hospital and rehabilitation stay, he did make signifi cant functional recovery on goal-directed medical therapy. Six months after transplantation, he developed symptoms concerning of heart failure. Acute cellular rejection was ruled out. A repeat echocardiogram showed mild to moderately depressed systolic function (stable posttransplant) and severe functional MR (vena contracta, 0.7 cm; proximal isovelocity surface area, 0.8 cm; eff ective regurgitant orifi ce area, 0.3 cm 2 ; systemic blunting of pulmonary venous fl ow) due to a retracted posterior leafl et and failure to coapt adequately (Figure 1) .
Given his medical comorbidities, poor functional status, and need for another sternotomy, he was deemed to be a high-risk surgical candidate. Th e decision was made for him to undergo treatment with a MitraClip. Th e procedure was performed using both fl uoroscopy and 3-dimensional transesophageal guidance. Th e standard right femoral venous approach was used to gain access for the MitraClip apparatus. A transseptal puncture was performed to gain access into the left atrium
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